Contributions
Abstract: PB1829
Type: Publication Only
Session title: Thrombosis and vascular biology - Biology & Translational Research
Background
Pulmonary embolism (PE) is reported in around 2.6–8.9% of COVID-19 hospitalized adult patients, but it is very rare in children and adolescents with symptomatic infection from SARS-CoV-2.
Aims
This is the case of a 15-year-old male patient with COVID-19 complicated by deep vein thrombosis (DVT) who developed PE.
Methods
The patient presented with fever and a four-day history of pain and swelling of the right lower limb, without any history of injury. It is notable that 15 days before admission, he experienced diarrhea, vomiting and low-grade fever for 48 hours. The adolescent boy had short stature and was rather overweighted for his age and gender (body mass index: 25.2 kg/m2), while over the last two years he was receiving anastrozole (aromatase inhibitor), for height increase.
Results
On admission, due to pain, limited mobility of the right limb and edema of the ipsilateral knee, a triplex ultrasound was performed that revealed DVT extended from the right iliac to the popliteal vein. RT-PCR for SARS-CoV-2 was positive, while the rest of the laboratory results showed a prolongation in prothrombin time (16.3 seconds, normal values: 10-14 sec), elevated d-dimers (10 mg/dl, n.v.: < 0.5 mg/dl), high levels of factor VIII (214 IU/dl, n.v: 50-150 IU/dl), low levels of antithrombin (36 IU/ml, n.v.: 80-120 IU/ml) and increased ferritin (346 μg/L, n.v.: 10-150 μg/L). Initial management consisted of antibiotic therapy plus anticoagulation with subcutaneous low molecular weight heparin (LMWH) i.e. tinzaparin in therapeutic dose. Soon after admission the patient developed severe hypotension with low diastolic blood pressure, refractive to IV normal saline boluses while his oxygen saturation dropped to 94% few hours later. A CT pulmonary angiogram (CTPA) was performed revealing a big thrombus with longitudinal diameter of 3 cm, in the left pulmonary artery, establishing the diagnosis of PE on the ground of DVT. After PE diagnosis, the patient was transferred to the intensive care unit (ICU) for 48 hours, and subsequently at the special SARS-CoV-2 ward for 4 weeks. He completed a ten-day course of intravenous dexamethasone and anticoagulation treatment was switched to oral warfarin, after completion of three weeks of LWMH. Apart from COVID-19 whose hypercoagulable physis is already well-established the patient had additional risk factors predisposing to thromboembolic episodes. More precisely, he was overweight and under aromatase inhibitor therapy (which can be procoagulant by increasing testosterone levels). Moreover, the preexisting symptoms from the gastrointestinal system, could have predisposed him to DVT in view of dehydration and increased viscosity. On top of it, it is noteworthy that the patient had excessive screen time for his tele-education the last three weeks prior to the onset of VTE, meaning there were long periods of immobilization. Additionally, during the course of COVID-19 infection he had low levels of antithrombin, a serious prothrombotic condition attributed to the disease.
Conclusion
This case underlines the fact that pediatric patients with COVID-19, are predisposed to the development of thromboembolic events, especially in the presence of preexisting prothrombotic risk factors. Larger studies in pediatric population with SARS-CoV-2 infection are needed, for the establishment of recommendations regarding risk evaluation, hemostatic monitoring and application of anticoagulation in outpatient, as well as hospitalized patients.
Keyword(s): COVID-19, Pulmonary embolism, Thrombosis
Abstract: PB1829
Type: Publication Only
Session title: Thrombosis and vascular biology - Biology & Translational Research
Background
Pulmonary embolism (PE) is reported in around 2.6–8.9% of COVID-19 hospitalized adult patients, but it is very rare in children and adolescents with symptomatic infection from SARS-CoV-2.
Aims
This is the case of a 15-year-old male patient with COVID-19 complicated by deep vein thrombosis (DVT) who developed PE.
Methods
The patient presented with fever and a four-day history of pain and swelling of the right lower limb, without any history of injury. It is notable that 15 days before admission, he experienced diarrhea, vomiting and low-grade fever for 48 hours. The adolescent boy had short stature and was rather overweighted for his age and gender (body mass index: 25.2 kg/m2), while over the last two years he was receiving anastrozole (aromatase inhibitor), for height increase.
Results
On admission, due to pain, limited mobility of the right limb and edema of the ipsilateral knee, a triplex ultrasound was performed that revealed DVT extended from the right iliac to the popliteal vein. RT-PCR for SARS-CoV-2 was positive, while the rest of the laboratory results showed a prolongation in prothrombin time (16.3 seconds, normal values: 10-14 sec), elevated d-dimers (10 mg/dl, n.v.: < 0.5 mg/dl), high levels of factor VIII (214 IU/dl, n.v: 50-150 IU/dl), low levels of antithrombin (36 IU/ml, n.v.: 80-120 IU/ml) and increased ferritin (346 μg/L, n.v.: 10-150 μg/L). Initial management consisted of antibiotic therapy plus anticoagulation with subcutaneous low molecular weight heparin (LMWH) i.e. tinzaparin in therapeutic dose. Soon after admission the patient developed severe hypotension with low diastolic blood pressure, refractive to IV normal saline boluses while his oxygen saturation dropped to 94% few hours later. A CT pulmonary angiogram (CTPA) was performed revealing a big thrombus with longitudinal diameter of 3 cm, in the left pulmonary artery, establishing the diagnosis of PE on the ground of DVT. After PE diagnosis, the patient was transferred to the intensive care unit (ICU) for 48 hours, and subsequently at the special SARS-CoV-2 ward for 4 weeks. He completed a ten-day course of intravenous dexamethasone and anticoagulation treatment was switched to oral warfarin, after completion of three weeks of LWMH. Apart from COVID-19 whose hypercoagulable physis is already well-established the patient had additional risk factors predisposing to thromboembolic episodes. More precisely, he was overweight and under aromatase inhibitor therapy (which can be procoagulant by increasing testosterone levels). Moreover, the preexisting symptoms from the gastrointestinal system, could have predisposed him to DVT in view of dehydration and increased viscosity. On top of it, it is noteworthy that the patient had excessive screen time for his tele-education the last three weeks prior to the onset of VTE, meaning there were long periods of immobilization. Additionally, during the course of COVID-19 infection he had low levels of antithrombin, a serious prothrombotic condition attributed to the disease.
Conclusion
This case underlines the fact that pediatric patients with COVID-19, are predisposed to the development of thromboembolic events, especially in the presence of preexisting prothrombotic risk factors. Larger studies in pediatric population with SARS-CoV-2 infection are needed, for the establishment of recommendations regarding risk evaluation, hemostatic monitoring and application of anticoagulation in outpatient, as well as hospitalized patients.
Keyword(s): COVID-19, Pulmonary embolism, Thrombosis